Icon (NASDAQ:ICLR) Rating Increased to Strong-Buy at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Icon (NASDAQ:ICLR) from a hold rating to a strong-buy rating in a research report sent to investors on Monday,Zacks.com reports.

Other analysts have also recently issued reports about the stock. Robert W. Baird set a $119.00 target price on shares of Icon in a research note on Friday, February 13th. Barclays upped their price target on shares of Icon from $185.00 to $200.00 and gave the stock an “equal weight” rating in a report on Monday, December 15th. Mizuho set a $216.00 price objective on Icon in a research note on Friday, January 9th. Truist Financial restated a “hold” rating and set a $222.00 target price (down from $231.00) on shares of Icon in a research report on Thursday, January 8th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Icon in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $157.47.

Icon Trading Up 5.0%

Shares of ICLR opened at $104.66 on Monday. Icon has a twelve month low of $66.57 and a twelve month high of $211.00. The stock has a market cap of $8.45 billion, a PE ratio of 14.16, a P/E/G ratio of 2.47 and a beta of 1.27. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. The business’s 50-day moving average price is $165.34 and its 200-day moving average price is $172.02.

Institutional Trading of Icon

Several hedge funds and other institutional investors have recently bought and sold shares of ICLR. Private Trust Co. NA raised its stake in shares of Icon by 200.0% during the third quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock worth $25,000 after acquiring an additional 94 shares in the last quarter. Toth Financial Advisory Corp purchased a new stake in shares of Icon in the 4th quarter valued at $27,000. EFG International AG bought a new position in shares of Icon during the 4th quarter valued at $27,000. Ameriflex Group Inc. purchased a new position in Icon in the 3rd quarter worth $33,000. Finally, Abound Financial LLC purchased a new position in Icon in the 4th quarter worth $54,000. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.